Research and Technology Management

Similar documents
New drugs in Acute Leukemia. Cristina Papayannidis, MD, PhD University of Bologna

Research and Technology Management

Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight

PRELIMINARY PROGRAM MAY 31 - JUNE 4, 2019

FACULTY MEMBERSHIP APPLICATION Tulane Cancer Center

NCCN National Comprehensive Cancer Network Directory Information

*Total award amount reflects Direct Costs only for the duration of the project

PERSONALIZED PSYCHO-ONCOLOGY

CONTRACTING ORGANIZATION: Memorial Sloan-Kettering Cancer Center New York, NY 10065

Enasidenib Monotherapy is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia

Facts On Leukemia By American Cancer Society

A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL

Genetic analysis and preclinical modeling of leukemic transformation of myeloproliferative neoplasms: Implications for therapeutic strategies

Genetics of MPNs insights from genomic and functional studies

The 2015 donations will be transformative:

Phase 2b trial met key clinical objectives and is being discontinued early by the sponsor

Grants & Contracts Awards

ENASIDENIB IN MUTANT-IDH2 RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML): RESULTS OF A PHASE 1 DOSE- ESCALATION AND EXPANSION STUDY

ASCO 2018 Summary of Presentation. May 16, 2018

ONCOLOGY MEDICAL HOME ACCREDITATION

Challenges in studying risk factors for childhood cancer

SKCC Protocol Review Committee New Study Application

Introduction to Oncology and Chemotherapy October 23-24, 2013 San Francisco, CA

Cancer Science nd International Conference on Oncology & Cancer Science. August 06-08, 2018 Berlin, Germany. Hosting Organization

Cancer Prevention & Control in Adolescent & Young Adult Survivors

SPECIAL AUTHORIZATION REQUEST FOR COVERAGE OF HIGH COST CANCER DRUGS

Founded in 2016 to develop life-changing therapies against debilitating aggressive cancers that have limited treatment options

Characteristics and Outcome of Therapy-Related Acute Promyelocytic Leukemia After Different Front-line Therapies

The conference will be held in English. There will be small group discussions and role play which requires proficiency in English

American Cancer Society, Inc. Extramural Grants

Please Silence Your Cell Phones. Thank You

Children s Oncology Group: What We Learned In The Merger Process

RESEARCH STUDY. Joan and Sanford I. Weill Medical College and Graduate School of Medical Sciences of Cornell University

Selinexor is an oral, slowly-reversible, first-inclass Selective Inhibitor of Nuclear Export (SINE)

Characterization of TRK fusions and therapeutic response to TRK inhibition in hematologic malignancies

I pediatric OncOlOgy

Corporate Medical Policy. Policy Effective February 23, 2018

Young Investigator Initiative for the Conduct of ACRIN Ancillary Research

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

The Clinical Research E-News

Breast Cancer in Childhood Cancer Survivors: The Impact of Screening on Morbidity

Company Overview. April Rewriting cancer treatment NASDAQ: EPZM

OMI Seminars The Children's Hospital of Philadelpia TBA. Matt O'Connor, MD TBA. Weill Cornell Medicine-NYP TBA. Frank Chervenak, MD

September 20, Submitted electronically to: Cc: To Whom It May Concern:

Online/Self-study courses

Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. Kevin G. McLure, PhD EpiCongress July 2014

Online/Self study courses

Scarce Resources are best Applied to Prevention The Anti Argument

AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC

Jonathan H. Schatz, MD N Campbell Avenue, Tucson, AZ, (office), (laboratory)

Bridging Treatment to Transplant and Current Advances

A World Free From Cancer. BC Cancer Foundation 2011 Report to Donors

HR 95% Confidence Interval. *no DFS events occurred in AJCC 7 stage I/II TNBC patients treated with NPS plus trastuzumab.

Introduction to Oncology: Focus on Solid Tumors October 22-23, 2014 San Francisco, CA

Genomic Methods in Cancer Epigenetic Dysregulation

RUNX1 and FPD/AML Translational Research. The Leukemia and Lymphoma Society / Babich Family Foundation Partnership. September 2016

American Cancer Society, Inc. Extramural Grants

2017 ST3 Competition Ratios Medical Specialties

The Advent of Immunotherapy in Cancer Therapy

Bihong Zhao, M.D, Ph.D Department of Pathology

Comparative Effectiveness Research of Robotic Surgeries for Cancer Treatment

Past Chapter Summaries Educational Topics Summary

Frontiers in Cancer Therapy. John Glod, M.D., Ph.D.

CSF1R Antibody LY , IMC-CS4. Drug Discovery Platform: Immuno-Oncology. Derived from Pixley FJ and Stanley ER. 1

HODGKIN S AND NON-HODGKIN S LYMPHOMA

ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015

National Cancer Institute Clinical Trial Cooperative Groups

PI3K/mTOR Dual Inhibitor

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development One Washington Circle Hotel, Washington, DC October 19-21, 2016

OVAC FY 2017 Appropriations Requests

St. Rita s Cancer Service Line Annual Report

GSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017

Insights into the Cell-of-Origin of the Histiocytoses Using Patient-Derived Xenograft Models

The Days of Miracles & Wonder... and Science

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

Elisabeth Koller 3rd Medical Dept., Center for Hematology and Oncology, Hanusch Hospital, Vienna, Austria

Thursday, August 9, :00 am 5:30 pm Registration Desk Open Atlantic Ballroom Foyer. 7:00 am 8:00 am Continental Breakfast Atlantic Ballroom Foyer

SU2C TOP SCIENCE ACCOMPLISHMENTS

oncogenes-and- tumour-suppressor-genes)

2010 Oncology Pharmacy Preparatory Review Course for Home Study Learning Objectives

Innate Immunity Dysregulation in Myelodysplastic Syndromes. CONTRACTING ORGANIZATION: University of Texas MD Anderson Cancer Center Houston, TX 77030

Examining Genetics and Genomics of Acute Myeloid Leukemia in 2017

Opposing effects of low versus high concentrations of vitamins/dietary ingredients Vitamin C and niacin on colon cancer stem cells (CSCs)

Together... The Strength to Fight Cancer. Annual Cancer Report December 2014

Chapter 3. Neoplasms. Copyright 2015 Cengage Learning.

Research For the Future. Len Lichtenfeld, MD, MACP Interim Chief Medical and Scientific Officer

RECENT TRENDS. The Impact of the NCI and NIBIB

Cancer: Pathophysiology, Current Therapies, Clinical Trials and Drug Development MicroTek Training Center Washington, DC October 17 19, 2018

Medicinae Doctoris ~ One university. Many futures.

Identifying Geographic & Socioeconomic Disparities in Access to Care for Pediatric Cancer Patients in Texas

Molecular. Oncology & Pathology. Diagnostic, Prognostic, Therapeutic, and Predisposition Tests in Precision Medicine. Liquid Biopsy.

SAMPLE. Survivorship Care Plan for Lymphoma (Diffuse Large B-Cell) General Information. Care team

EASTERN PAIN ASSOCIATION 2018 ANNUAL MEETING

TUESDAY, 18th OCTOBER, 2016 / DAY -2. THE SPENCER HOTEL Hall A Hall B (St. Lukes Hospital)

Radiation Oncology Study Guide

AVEO and Astellas Report Final Overall Survival Results from TIVO-1

ALBERTA PRINCIPAL INVESTIGATORS

CLINICAL RESEARCH IN GEORGIA UPDATE. Nancy M. Paris, MS, FACHE President, Georgia CORE September 6, 2014

Changes from Third Quarter Flash Report for the Fiscal Year ending March 2015 announced on February 3, 2015 *1: Marketing authorization of Onoact 150

Transcription:

Grants & Contracts Awards Processed by Grants & Contracts Join us as we congratulate the investigators listed below who have recently received a new or competitive renewal award (Based on information available in Grants Central as of 3/1/13): *Total award amount reflects Direct Costs only for the duration of the project February 2013 Principal Investigator: Jacqueline F. Bromberg, MD, PhD Department/Program: Medicine/Breast Cancer Project Title: Characterization and Functional Analysis of Breast Cancer-Derived Exosomes in Malignant Progression Total Award* Amount: $96,080 Award Date: 02/08/13 Project Duration: 5 Years Awarding Agency: Weill Medical College of Cornell University/National Institutes of Health Principal Investigator: Ross Levine, MD Department/Program: Medicine/Human Oncology & Pathogenesis Program (HOPP) Project Title: Role of TET2 Mutations in Malignant Transformation and Acute Myeloid Leukemia Total Award* Amount: $2,375,521 Award Date: 02/07/13 Project Duration: 5 Years Awarding Agency: National Cancer Institute Principal Investigator: Ana Ortega Molina, PhD Department/Program: Cancer Biology & Genetics Project Title: Epigenetics of Lymphoid Malignancies Total Award* Amount: $157,143 Award Date: 02/01/13 Awarding Agency: Leukemia and Lymphoma Society Principal Investigator: Chris Sander, PhD Department/Program: Epidemiology & Biostatistics/Biostatistics/Computational Biology Project Title: TARGET Analysis Portal Proposal Total Award* Amount: $186,502 Award Date: 02/01/13 Awarding Agency: SAIC-Frederick/National Cancer Institute 1 Memorial Sloan-Kettering Cancer Center

Principal Investigator: Lorenz Studer, MD Department/Program: Neurosurgery/Departmental/Developmental Biology Project Title: Oculomotor Resistance in ALS Total Award* Amount: $94,300 Award Date: 02/20/13 Awarding Agency: Project A.L.S. Principal Investigator: Larissa K.F. Temple, MD, FACS, FRCS(C) Department/Program: Surgery/Colorectal Project Title: Randomized Early Intervention Study to Improve Bowel Function in SPS Patients Total Award* Amount: $49,376 Award Date: 02/13/13 Awarding Agency: American Society of Colon and Rectal Surgeons Principal Investigator: Talia Zaider PhD Department/Program: Psychiatry Project Title: Theraputic Pathways to Improving End of Life Outcomes Among Families in Palliative Care Total Award* Amount: $24,250 Award Date: 02/11/13 Project Duration: 4 Years Awarding Agency: National Cancer Institute INTERNAL COMPETITION Principal Investigator: John Chodera, PhD Department/Program: Computational Biology Award Date: 02/01/13 January 2013 Principal Investigator: Cameron Brennan, MD Department/Program: Neurosurgery Project Title: Elucidating Mechanisms of Histone H3.3 Mutants-Mediated Oncogenesis in Pediatric Brain Cancers Total Award* Amount: $70,000 2 Memorial Sloan-Kettering Cancer Center

Principal Investigator: Yu Chen, MD Department/Program: Human Oncology & Pathogenesis Program (HOPP) Project Title: Elucidating Mechanisms of Histone H3.3 Mutants-Mediated Oncogenesis in Pediatric Brain Cancers Total Award* Amount: $208,000 Principal Investigator: Ping Chi, MD Department/Program: Medicine Project Title: Elucidating Mechanisms of Histone H3.3 Mutants-Mediated Oncogenesis in Pediatric Brain Cancers Total Award* Amount: $70,000 Award Date: 01/14/13 Principal Investigator: Jarrod Dudakov, PhD Department/Program: Immunology Project Title: Role of Interleukin-22 (IL-22) in Thymic Function Total Award* Amount: $100,000 Award Date: 01/25/13 Awarding Agency: American Society of Hematology Principal Investigator: Ira J. Dunkel, MD Department/Program: Pediatrics Project Title: Children's Oncology Group: Per Case Reimbursement from NIH COG Chair Grant Total Award* Amount: $12,500 Awarding Agency: Children's Hospital of Philadelphia/National Cancer Institute Principal Investigator: Emily Foley, PhD Department/Program: Cell Biology 3 Memorial Sloan-Kettering Cancer Center

Principal Investigator: Alan M. Hanash, MD, PhD Department/Program: Medicine Project Title: IL-22, Innate Lymphoid Cells, and the Protection of Epithelial Tissues from GVHD Total Award* Amount: $150,000 Award Date: 01/25/13 Awarding Agency: American Society of Hematology Principal Investigator: Daniel Heller, PhD Department/Program: Molecular Pharmacology & Chemistry Principal Investigator: Ross Levine, MD Department/Program: Medicine/Human Oncology & Pathogenesis Program (HOPP) Project Title: Discovery of AID-dependent Epigenetic Mechanisms in Hematological Malignancies Total Award* Amount: $166,666 Principal Investigator: Ross Levine, MD Department/Program: Medicine/Human Oncology & Pathogenesis Program (HOPP) Project Title: Therapeutic Targeting of IDH1 and IDH2 Mutations in Acute Myeloid Leukemia (AML) and Chondrosarcoma Total Award* Amount: $249,778 Principal Investigator: Wendy G. Lichtenthal, PhD Department/Program: Psychiatry & Behavioral Sciences Project Title: Survivorship Project: ACS and MSKCC Collaboration to Adapt and Refine Meaning-Centered Group Psychotherapy for Breast Cancer Survivors Through Focus Groups and Intervention Evaluations Total Award* Amount: $384,424 Award Date: 01/23/13 Awarding Agency: American Cancer Society 4 Memorial Sloan-Kettering Cancer Center

Principal Investigator: Brian P. Marr, MD Department/Program: Surgery/Ophthalmic Oncology Project Title: Development of sd-rxrnas as Therapy for Retinoblastoma and Other Malignancies Total Award* Amount: $13,059 Award Date: 01/30/13 Awarding Agency: RXi Pharmaceuticals/ National Cancer Institute Principal Investigator: Joseph R. Osborne, MD, PhD Department/Program: Radiology/Molecular Imaging and Therapy Project Title: Immuno-PET With Anti-PSMA 89Zr-J591 mab For Molecular Imaging of Prostate Cancer Total Award* Amount: $108,750 Award Date: 01/28/13 Project Duration: 7 Months Awarding Agency: National Cancer Institute Principal Investigator: Cindy Puente, MA Department/Program: Cell Biology Project Title: Sensing and Relaying Autophagic Signaling by Ulk Kinase Complex Total Award* Amount: $126,696 Award Date: 01/25/13 Awarding Agency: National Institute of General Medical Sciences Principal Investigator: Raajit K. Rampal, MD, PhD Department/Program: Human Oncology & Pathogenesis Program (HOPP) Project Title: The Role of WT1 in Epigenetic Alterations in Acute Myeloid Leukemia Total Award* Amount: $100,000 Award Date: 01/17/13 Awarding Agency: American Society of Hematology Principal Investigator: Gary Schwartz, MD Department/Program: Medicine/Melanoma and Sarcoma Project Title: Therapeutic Targeting of IDH1 and IDH2 Mutations in Acute Myeloid Leukemia (AML) and Chondrosarcoma Total Award* Amount: $249,778 Principal Investigator: Martin S. Tallman, MD Department/Program: Medicine/Leukemia 5 Memorial Sloan-Kettering Cancer Center

Project Title: ECOG and ACRIN Consolidation Total Award* Amount: $13,430 Award Date: 01/09/13 Awarding Agency: Eastern Cooperative Oncology Group/National Cancer Institute Principal Investigator: Richard White, MD, PhD Department/Program: Cancer Biology & Genetics INTERNAL COMPETITION Principal Investigator: Samuel Danishefsky, PhD Department/Program: Molecular Pharmacology & Chemistry Project Title: Testing the Immunogenicity of a New Unimolecular Vaccine Total Award* Amount: $50,000 Award Date: 01/23/13 Awarding Agency: Experimental Therapeutics Center 6 Memorial Sloan-Kettering Cancer Center